Endovascular Treatment of Cerebral AVM with Onyx - Initial Experience

Joseph, Santhosh; Chadaga, Harsha; Murali, K.

doi:10.1177/15910199050110s121

Cited by 7 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other embolic agents with similar features to Phil are available on the market, particularly Onyx (Medtronic, Dublin, Ireland) and Squid (Emboflu, Gland, Switzerland) [ 26 , 27 , 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…All these three embolic agents are available in different concentrations: In particular, in addition to the different Phil concentrations listed above, Onyx is available as Onyx18 (lower viscosity) or Onyx 34 (higher viscosity), while Squid is available as Squid12 (lower viscosity), Squid18 (standard viscosity), and Squid34 (higher viscosity); the different concentrations available for Phil have been described above [ 26 , 27 , 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions

Lucatelli

Corona

Teodoli

et al. 2021

JCM

View full text Add to dashboard Cite

Objective: To evaluate the safety and efficacy of the Phil liquid embolic agent in non-neurological embolization procedures. M&M: Thirty-five patients with a mean age of 62.5 years underwent percutaneous embolization using Phil for the treatment of visceral arterial bleedings in 20/35 patients (including three gluteal, one bladder, two superior mesenteric, three epigastric, one deep femoral, five internal iliac, four intercostal, and one lingual arteries), splanchnic pseudoaneurysms in 11/35 patients (including three hepatic, five splenic, and three renal arteries), pancreatic bleeding metastasis in 1/35 patient, and gastric bleeding varices in 3/35 patients. Phil is composed of a non-adhesive copolymer dissolved in DMSO (Anhydrous Dimethyl Sulfoxide) with different viscosity. Procedures were performed slowly under continuous fluoroscopic guidance to avoid embolization of non-target vessels. Results: Clinical success was obtained with a single intervention in 34 cases (97.15%), while a repeated procedure was required in one case (2.85%). No technical complications nor non-target embolization occurred. A case of post-embolic syndrome was noted (2.85%) in one patient. DMSO administration-related pain was successfully controlled by medical therapy. Conclusion: Phil can be considered a safe and effective embolic agent for the treatment of non-neurologic bleeding.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Use of Phil Embolic Agent for Bleeding in Non-Neurological Interventions

Lucatelli

Corona

Teodoli

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Initial experiences using the Onyx system in the endovascular treatment of cerebral AVMs has been reported in single and multicenter studies (17,18,(28)(29)(30)(31)38). The results are promising, including achievement of long-duration injections (29) and improved angiographic outcomes (28).…”

Section: Discussionmentioning

confidence: 99%